Drug Type Biosimilar, Monoclonal antibody |
Synonyms Denosumab Biosimilar (Curateq Biologics Pvt Ltd.), 地舒单抗生物类似药(Curateq Biologics Pvt Ltd.), BP 16 + [4] |
Target |
Action inhibitors |
Mechanism RANKL inhibitors(Tumor necrosis factor ligand superfamily member 11 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |


| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D03684 | Denosumab Biosimilar(CuraTeQ) |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Osteoporosis, Postmenopausal | Phase 3 | India | 26 Nov 2023 |
Phase 1 | - | 204 | ffokkpewps(apronndlee) = PD profiles of sCTX using percent change from baseline evaluated in terms of Emax and AUEC0-t was found to be comparable between the three treatment arms. tdjvydmbqc (pygzgkjvzh ) View more | Positive | 16 Apr 2026 | ||
EU-Prolia | |||||||
Company_Website Manual | Phase 3 | 446 | obxveqfcuy(xivyngoaph) = achieved the pre-defined equivalence margin of (-1.45, +1.45) twolubljmb (rzuwrrvjmo ) Met View more | Non-inferior | 19 Sep 2025 | ||






